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Background: With the well established shift to neoadjuvant treatment for locally advanced rectal cancer,
there is increasing focus on the use of radiosensitizers to improve the efficacy and tolerability of
radiotherapy. There currently exist few randomized data exploring novel radiosensitizers to improve
response and it is unclear what the clinical endpoints of such trials should be.
Methods: A qualitative systematic review was performed according to the PRISMA guidelines using
preset search criteria across the PubMed, Cochrane and Scopus databases from 1990 to 2017. Additional
results were generated from the reference lists of included papers.
Results: A total of 123 papers were identified, of which 37 were included; a further 60 articles were
obtained from additional referencing to give a total of 97 articles. Neoadjuvant radiosensitization for
locally advanced rectal cancer using fluoropyrimidine-based chemotherapy remains the standard of
treatment. The oral derivative capecitabine has practical advantages over 5-fluorouracil, with equal
efficacy, but the addition of a second chemotherapeutic agent has yet to show a consistent significant
efficacy benefit in randomized clinical assessment. Preclinical and early-phase trials are progressing with
promising novel agents, such as small molecular inhibitors and nanoparticles.
Conclusion: Despite extensive research and promising preclinical studies, a definite further agent in
addition to fluoropyrimidines that consistently improves response rate has yet to be found.
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Introduction
Rectal cancer treatment has continued to improve in
recent years as a result of optimized surgical technique,
advances in staging, pathological quality control andmulti-
disciplinarymanagement.Neoadjuvant chemoradiotherapy
(CRT) is considered the standard of care for locally
advanced rectal cancer (LARC). It is well recognized that
the response to neoadjuvant CRT is both variable and
unpredictable for the individual patient, and techniques to
risk-stratify patients and predict response are an expand-
ing area of research. Favourable responses to CRT are
independently associated with conferring a long-term
survival advantage to patients who undergo resection, and
in more recent years the possibility of deferral of surgery
and organ preservation has also been raised1.
A complete response to CRT may be classified as either
a clinical complete response (cCR) or a pathological
complete response (pCR). Although the two terms are
often used interchangeably, these responses are assessed
differently, and one does not necessarily imply the other.
A pCR is based on pathological findings after resec-
tion, commonly using the Dworak or Mandard tumour
regression grading systems. A cCR is defined accord-
ing to a combination of clinical examination (including
digital rectal examination), radiological (in particular
diffusion-weighted MRI) and endoscopic appearances.
Following the initial description by Habr-Gama and
colleagues2, there are now a growing number of series
reporting the use of neoadjuvant CRT as the sole treat-
ment for rectal cancer that undergoes a cCR, resulting in
further interest in the role of organ preservation in rectal
cancer3. It is, however, important to be able to differen-
tiate which tumours are more susceptible to undergoing a
cCR. At present, the most reliable predictor of an increased
response is tumour stage, with early tumours more likely
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Fig. 1 Summary of current and potential radiosensitizing agents. 5-dFCR, 5′-deoxy-5-fluorocytidine; 5-dFUR, 5′-deoxy-5-
fluorouridine; 5-FU, 5-fluorouracil; dUMP, deoxyuridine monophosphate; dTMP, deoxythymidine monophosphate; SSB, single-strand
break; DSB, double-strand break; TOPO, topoisomerase; EGFR, epidermal growth factor receptor; VEGF, vascular endothelial
growth factor; PARP, poly(ADP-ribose)polymerase; COX, cyclo-oxygenase; HDAC, histone deacetylase
to display a cCR. The use of CRT in combination with
local excision is perhaps becoming better defined in early
T1 rectal cancers, but its value in more advanced cancer is
less clear4. The STAR-TReC trial (ISRCTN14240288)5
will compare three different strategies for more advanced
tumours up to T3b N0, and assess the feasibility of ran-
domizing to a trial with organ preservation arms. However,
the role of neoadjuvant CRT as sole treatment for even
more locally advanced tumours that perhaps threaten the
circumferential resection margin (CRM) is unknown, and
it is likely that studies examining such tumours will need to
incorporate the development of intensified CRT regimens.
Patients who have an apparent cCR may be offered entry
into a watch-and-wait surveillance policy after a full and
complete discussion. If patients are fit for intervention,
salvage surgery is recommended for those who display
tumour regrowth, which is most often luminal rather than
nodal1. There is clearly an interest in both predicting
patients whomay undergo a cCR or pCR and/or improving
cCR and/or pCR rates as there are currently no reliable
clinical (apart from earlier stage), biochemical or molecular
predictive biomarkers in clinical practice.
Radiotherapy (RT) is typically delivered via either a
short- or long-course strategy, the latter being employed
to downstage tumours. A recent short study by the UK
National Bowel Cancer Audit6 revealed that the median
time from completion of CRT to surgical resection is
currently 11weeks in the UK, suggesting that the con-
cept of delayed resection is gaining traction in clinical
practice. A recent study7 suggested that increasing the
interval between the end of CRT and surgical resection
improves the response rate. Similarly, short-course RTmay
be combined with a delayed interval to surgery; the recent
Stockholm III trial8 has demonstrated improved tumour
regression over traditional short-course treatment.
Radiosensitizers are employed routinely to improve the
radiosensitivity of rectal cancer to RT; the standard of
care is a concurrent single-agent fluoropyrimidine. A num-
ber of studies have analysed novel agents or combination
therapies that aim to improve radiosensitivity and cCR
and/or pCR rates. The critical target for RT is DNA
and the accumulation of DNA damage, particularly DNA
double-strand breaks, and the ability of tumour cells to
repair this damage, contributes significantly to the thera-
peutic effect. Some agents and combination therapies (such
as oxaliplatin, irinotecan and poly(ADP-ribose) polymerase
(PARP) inhibitors) might typically take advantage of this
by creating additional DNA damage or inhibiting DNA
damage repair, exacerbating the effects of RT. The aim of
this review was to summarize the current and novel agents
© 2018 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2018; 105: 1553–1572
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Fig. 2 PRISMA diagram showing selection of articles for review
that have been employed in the treatment of LARC, and to
consider their role in the context of cCR and organ preser-
vation. A summary of radiosensitizing agents is provided in
Fig. 1.
Methods
A literature search was performed for published full-text
articles using PubMed, Cochrane and Scopus databases
using the search criteria string (‘radiosensitiser’ OR
‘radiosensitizer’) AND (‘rectal’ OR ‘rectum’) AND ‘can-
cer’ in November 2017. Additional papers were detected
by scanning the references of relevant papers. Search
results were initially included based on a relevant title, and
these papers were then read in full. Inclusion criteria were:
papers published in the English language, those with a
focus on rectal cancer, all study types, and articles published
between 1990 and 2017. Studies focusing on a primary
malignancy other than rectal cancer were excluded. Two
reviewers were involved at each stage, with search results
being loaded into the Covidence system to enable joint
reviews to take place methodically. Once eligible articles
had been identified, a search was undertaken to exclude
duplicated results or duplicated data sets to produce the
final list of papers included (Fig. 2).
Standard chemotherapy regimens
5-Fluorouracil
5-Fluorouracil (5-FU) is an antimetabolite fluoropyrim-
idine. It is one of the most common chemotherapeu-
tic agents used in cancer treatment, in particular breast
and colorectal cancer. It was the first agent to be used
as a radiosensitizer in conjunction with RT, predomi-
nantly in colorectal cancer. It works by inhibiting essential
biosynthetic processes, and also by affecting cellular DNA
and RNA functions. The mechanism of cytotoxicity of
5-FU has been ascribed to the misincorporation of fluoro-
nucleotides into RNA and DNA, and to inhibition of the
nucleotide synthetic enzyme thymidylate synthase9.
There are a number of mechanisms by which 5-FU could
increase radiation sensitivity at the cellular level. One is
thought to involve the killing of S-phase cells, which are
relatively radioresistant10,11. This does not account for all
of the increased radiation sensitivity produced by the drug
because non-cytotoxic concentrations can also increase
sensitivity. Radiosensitization under non-cytotoxic condi-
tions occurs only when cells are incubated with the drug
before and during radiation treatment. Several studies have
suggested that 5-FU should be given continuously during
a course of fractionated radiation to achieve radiosensi-
tization of most fractions12,13. UK National Institute for
Health and Care Excellence guidance14 focusing on stage
III tumours, examining randomized comparisons of bolus
versus infusional regimens, suggests that infusional ther-
apy is equivalent to bolus treatment in terms of effective-
ness, but has relatively reduced toxicity. Owing to concerns
regarding the increased cost of infusional treatment and
patient inconvenience, there remains geographical varia-
tion across the UK in the technique employed14, although
5-FU has largely been superseded by oral capecitabine.
Trials of 5-FU are summarized in Table 1.
Krook and colleagues15 first conducted an RCT to
assess adjuvant RT with or without systemic bolus 5-FU
chemotherapy, and confirmed an improvement in local
relapse rates with a survival benefit in favour of 5-FU-based
RT in comparison with RT alone. The phase III French
Federation Francophone de Cancerologie Digestive
(FFCD) 9203 study16 randomized patients with stage
II–III rectal cancer to receive RT alone or with infusional
5-FU/leucovorin. Patients in both arms subsequently
underwent surgery and four cycles of 5-FU/leucovorin.
The preoperative chemoradiation arm showed a sig-
nificant improvement in pCR rate (11⋅4 versus 3⋅6 per
cent; P< 0⋅050) and local relapse rate (8⋅1 versus 16⋅5 per
cent; P< 0⋅050). The 5-year survival in both arms was 67
per cent.
© 2018 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2018; 105: 1553–1572
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TheNational Surgical Adjuvant Breast andBowel Project
(NSABP) R-03 phase III study17 compared the use of
neoadjuvant and adjuvant CRT in patients with T3–T4
or node-positive rectal cancer using 5-FU and leucovorin.
Those receiving neoadjuvant therapy had a pCR rate of
15⋅0 per cent and 5-year disease-free survival (DFS) rate
of 64⋅7 per cent. Among those undergoing adjuvant CRT,
39⋅2 per cent had sphincter-saving surgery (versus 47⋅8 per
cent in the neoadjuvant cohort) and a DFS rate of 53⋅4 per
cent. Five-year overall survival rates were 74⋅5 and 65⋅6
per cent in the neoadjuvant and adjuvant treatment groups
respectively, supporting the use of CRT before rather than
after operation. In a 2012 Cochrane review, Petersen and
colleagues26 considered the use of 5-FU for additional
adjuvant chemotherapy. The pooled data from 21 RCTs,
including almost 10 000 patients, found improved DFS
and overall survival with use of adjuvant chemotherapy.
Owing to lack of tumour stage-specific data, however,
it was not possible to draw a link of benefit to specific
locally advanced tumours, potentially indicating an area
for further work.
The phase III European Organisation for Research
and Treatment of Cancer (EORTC) 22921 study18
randomized patients with stage II–III rectal cancer to
neoadjuvant RT alone versus RT with concurrent bolus
5-FU/leucovorin, with subsequent randomization to post-
operative chemotherapy or not. The authors concluded
that adding 5-FU-based chemotherapy, either before (as
part of CRT) or after operation, conferred a significant
advantage in terms of local control.
The German Rectal Cancer Study Group19 randomly
assigned 823 patients with clinical stage T3 or T4 or
node-positive disease to receive either preoperative or
postoperative CRT. The results showed a significantly
lower 5-year cumulative incidence of local relapse in favour
of the preoperative treatment group (6 versus 13 per cent;
P= 0⋅006). Five-year DFS (68 versus 65 per cent) and over-
all survival (76 versus 74 per cent) rates were similar. Sig-
nificant tumour downstaging was seen after preoperative
combined treatment, with a pCR rate of 8 per cent.
In a pooled analysis of 5-FU phase II–III trials27 includ-
ing 3157 patients, the pCR rate was 13⋅5 per cent. On
multivariable analysis, statistically significant factors for a
higher pCR rate were the addition of a second chemother-
apy agent and the method of continuous infusion.
Capecitabine
The development of an oral 5-FU drug was driven by
the desire to overcome the perceived limitations associ-
ated with intravenous infusion of 5-FU, such as extended
hospital stay, the need for intravenous lines and associated
healthcare costs. Capecitabine (Xeloda®; Roche, Basle,
Switzerland) is an oral prodrug of 5-FU; it is a fluoro-
pyrimidine carbamate that undergoes a three-step in vivo
enzymatic conversion to 5-FU. The final step is mediated
by the enzyme thymidine phosphorylase, which is upreg-
ulated in tumour tissue compared with adjacent healthy
tissue. This theoretically allows selective activation of the
drug and low systemic toxicity28. After oral administration,
capecitabine passes rapidly and extensively through the
intestinal membrane as an intact molecule. Capecitabine
is not cytotoxic itself; the only cytotoxic moiety is 5-FU,
which is generated preferentially in human cancer cells.
Preferential activation of capecitabine to 5-FU in malig-
nant tumour was demonstrated in animal models bearing
human xenografts29.Table 1 provides an overview of clinical
trials of capecitabine.
The first phase II trials20,21 showed that RT plus
capecitabine is well tolerated and easier to administer
than protracted intravenous infusion of 5-FU, with a
pCR rate comparable to intravenous infusion of 5-FU for
LARC. In 2008, another phase II trial22 of 31 patients
with LARC showed that capecitabine was well tolerated
orally and had radiosensitizing effects comparable to
those of neoadjuvant 5-FU therapy. In 2011, Swellen-
grebel et al.30 again showed that oral capecitabine had
an acceptable acute toxicity profile in a cohort of 147
patients with LARC. In 2015, Saha and co-workers23
conducted a randomized control pilot study comparing
capecitabine–oxaliplatin (CAPOX) as a radiosensitizer
with 5-FU–leucovorin; the two arms were comparable in
terms of objective response rate, pCR rate, R0 resection
and toxicity profile23. Noh and colleagues31,32 investigated
different timings for administration of capecitabine among
171 patients undergoing RT followed by total mesorectal
excision (TME) 4–6weeks after neoadjuvant therapy and
assessed the radiosensitization response by pCR. The opti-
mal radiosensitizing effects of capecitabine were achieved
if it was administered 1 h before RT.
A phase III RCT24 between 2002 and 2007 recruited
nearly 400 patients with stage II and III LARC, comparing
CRTwith capecitabine versus 5-FU. The primary endpoint
was 5-year overall survival, which in the capecitabine group
was non-inferior to that in the 5-FU group (76 versus 67
per cent; P< 0⋅001). The local recurrence rate was similar
in the two groups (6 versus 7 per cent); however, the rate of
distant metastasis was 9 per cent lower in the capecitabine
group, with increased 3-year DFS.
The phase III NSABP R-04 trial25 aimed to ascertain the
optimal neoadjuvant chemotherapy regimen alongside RT
for stage II–III rectal cancer. Infusion of 5-FU and oral
© 2018 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2018; 105: 1553–1572
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Table 1 Summary of fluoropyrimidine agents
Results (%)*
Reference Phase
Disease
stage Test drug
Single/
combination
regimen Cohort size pCR rate cCR rate Other endpoints Toxicity
15 III T3–4N–/+ 5-FU Adjuvant RT
versus
RT+5-FU
204 n.a. – 5-year recurrence
41⋅5 (62⋅7)
Increased risk of
GI or haema-
tological
problems with
5-FU use; only
1 severe
16 III T3–4N+/– 5-FU Neoadjuvant
RT versus
RT+5-FU
773 11⋅4 (3⋅6) – 5-year LR 8⋅1
(16⋅5)
5-year OS 67 (67)
Grade 3–4
toxicity 14⋅6
(3⋅6)
17 III T3–4N–/+ 5-FU Neoadjuvant
versus
adjuvant
RT+5-FU
267 15⋅0 0⋅8 5-year DFS 64⋅7
(53⋅4)
5-year OS 74⋅5
(65⋅6)
Grade 4 GI
disturbance 24
(13)
18 III T3–4N–/+ 5-FU Neoadjuvant
RT versus
RT+5-FU
1011 13⋅7 (5⋅3) – – –
19 III T3–4N–/+ 5-FU Neoadjuvant
versus
adjuvant
RT+5-FU
823 8 – 5-year LRR 6 (13)
5-year DFS 68 (65)
5-year OS 76 (74)
Grade 3–4
toxicity 27
versus 40
20 II T3–4N–/+ Capecitabine Single 95 12 – Downstaging 76 Grade 3 toxicity
3
21 II T3–4N–/+ Capecitabine Single 54 18 – Downstaging 51
Sphincter salvage
67
Grade 3–4 GI
toxicity 2
22 II T3–4N–/+ Capecitabine Single 31 7 – Downstaging 54
3-year DFS 60
3-year OS 77
Grade 3–4 GI
toxicity 36
Proctitis 32
23 III T3–4N–/+ Capecitabine Capecitabine +
oxaliplatin
versus 5-FU
42 24 (14) – Downstaging 81
(67)
Grade 3 GI
toxicity 19 (14)
Haematological
19 (14)
24 III T3–4N–/+ Capecitabine Capecitabine
versus 5-FU
392 14 (5) – LR 6 (7)
5-year OS 76 (67)
3-year DFS 75 (67)
Grade 3–4 GI
toxicity 9 (2)
25 III T3–4N–/+ Capecitabine Capecitabine
+/–
oxaliplatin
versus 5-FU
+/–
oxaliplatin
1608 20⋅7 (17⋅8) – Downstaging 21⋅1
(21⋅3)
Sphincter salvage
59⋅3 (59⋅4)
Grade 3–5 GI
toxicity 11⋅7
(11⋅7)
Addition of
oxaliplatin
increased GI
disturbance
(P<0⋅001)
*Results for control group are shown in parentheses. pCR, pathological complete response; cCR, clinical complete response; 5-FU, 5-fluorouracil; RT,
radiotherapy; n.a., not applicable; GI, gastrointestinal; LR, local recurrence; OS, overall survival; DFS, disease-free survival; LRR, locoregional
recurrence.
capecitabine with or without intravenous oxaliplatin were
compared in 1608 patients. The pCR rate was 17⋅8 per cent
for those receiving 5-FU and 20⋅7 per cent among those
receiving capecitabine. Sphincter salvage rates were largely
comparable between the groups at 59⋅4 and 59⋅3 per cent
respectively, as were rates of tumour downstaging (21⋅3
versus 21⋅1 per cent). The addition of oxaliplatin led to a
small increase in pCR rate, but a reduction in sphincter sal-
vage and downstaging, and a significant increase in toxicity.
Additional chemotherapy agents to enhance
radiosensitivity
Oxaliplatin
Oxaliplatin is a third-generation platinum-based drug that
enhances radiation-induced cytotoxicity via irreparable
DNA damage through formation of interstrand and
intrastrand crosslinks, induction of G2/M cell-cycle
arrest, blockage of DNA replication and inhibition
© 2018 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2018; 105: 1553–1572
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of transcription33,34. Preclinical data indicated potent
radiosensitizing properties of the drug, with synergism
between oxaliplatin and RT35,36; these findings have been
applied to several clinical trials for patients with LARC.
Phase I–II studies focusing on the addition of oxali-
platin to 5-FU-based neoadjuvant CRT reported promis-
ing results33. pCR rates varied between 7 and 28 per cent,
comparedwith 8–15 per cent in the 5-FU-alone group34,37.
Single weekly dosing was the most effective regimen, with
diarrhoea and neuropathy the most commonly reported
adverse effects.
Six large phase III trials to date have compared fluoro-
pyrimidine CRT with or without oxaliplatin. The results
from these trials are summarized in Table 2. The
ACCORD12/prodige 2 trial38 randomized 598 patients
to standard capecitabine-based neoadjuvant CRT or addi-
tional weekly dosing with oxaliplatin together with an
increased radiation dose. The difference in pCR rate of
13⋅9 versus 19⋅2 per cent was not significant (P= 0⋅09),
although ACCORD had been powered to detect an
increase from 11 to 20 per cent with CAPOX. There was
an increase in grade 3–4 toxicity with oxaliplatin.
The CAO/ARO/AIO-04 study39, which included over
1000 participants, was the only trial to find a significantly
improved pCR rate with oxaliplatin (from 13 to 17 per
cent; P= 0⋅038). This was also the only trial to report an
advantage for oxaliplatin in terms of 3-year DFS (71⋅2 to
75⋅9 per cent). There were no significant differences in
grade 3–4 toxicities or postoperative complications. How-
ever, the infusional 5-FU regimen was changed between
the control and experimental arms, with oxaliplatin being
added to 16weeks of postoperative adjuvant chemother-
apy compared with 16weeks of bolus 5-FU alone in the
control arm; this means that the relative contributions of
oxaliplatin in CRT compared with adjuvant chemotherapy
are difficult to define.
The NSABP R-0440 and PETACC-641 trials, published
only in abstract form, found that addition of oxaliplatin
to 5-FU-based neoadjuvant therapy led to decreased treat-
ment compliance and increased toxicity, with no associated
improvement in pathological tumour downstaging. The
STAR-01 trial42 randomized 747 patients to standard 5-FU
chemotherapy or additional oxaliplatin. Interim analysis
detected no difference in pCR and toxicity problems with
the addition of oxaliplatin42.
Interestingly, initial results from the Chinese FOWARC
trial43 showed that use of a modified FOLFOX (oxali-
platin, leucovorin, 5-FU) 6 regimen in addition to
5-FU+RT gave significantly improved rates of pCR
compared with single-agent 5-FU+RT (27⋅5 versus 14⋅0
per cent respectively). The trial also showed comparable
downstaging and acceptable toxicity in patients with stage
II–III disease, and good compliance. Long-term data are
awaited and may still be important for future practice.
The evidence at present, including subsequent
meta-analyses49,50, still supports the use of a single-agent
fluoropyrimidine as the standard of care because of a lack
of consistent improvement in pCR and 3-year DFS rates51
with the combined regimen, and the greater toxicity due
to oxaliplatin52.
Irinotecan
Irinotecan, a topoisomerase (TOPO) 1 inhibitor, inhibits
religation of single-strandDNA breaks through the forma-
tion of camptothecin 11–TOPO-1–DNA complexes53. A
preclinical study54 has demonstrated irinotecan to be not
only a feasible addition to 5-FU chemotherapy, but also
a potent radiosensitizing agent in colorectal cancer, even
under hypoxic conditions.
In a small phase I trial in 2008, Choi et al.55 examined
the addition of weekly irinotecan to traditional 5-FU neo-
adjuvant CRT in 16 patients with locally advanced T3–T4
rectal cancers. Some 94 per cent of patients were eligible
to progress with surgical resection at the time of restaging,
with 93 per cent achieving a R0 resection. In eight patients
the disease was downstaged based on the TMN classifica-
tion, with a pCR rate of 25 per cent. Although the numbers
were too small to draw any firm conclusions, the evidence
was promising in terms of combination potential.
Mehta and colleagues56 conducted a phase II trial with
the same dosing strategy in a cohort of 32 patients, of
whom 38 per cent achieved a pCR and 71 per cent TNM
downstaging. However, 56 per cent experienced acute tox-
icity with an initial dose of 50mg/m2, requiring dose alter-
ation or delay in administration. Overall, small phase II
studies44–46,56 focusing on this approach have achieved
pCR rates of 14–37 per cent and tumour downstaging in
24–71 per cent. A summary of these trials is provided in
Table 2.
Mohiuddin et al.47 reported 5-year outcomes on 106
patients randomized to either basic 5-FU CRT or addi-
tional 4-week doses of 50mg/m2 irinotecan. They reported
an increase in overall survival of 14 per cent with the addi-
tion of irinotecan; however, the locoregional recurrence
rate was 17 per cent, compared with 16 per cent with-
out irinotecan, and respective distal recurrence rates were
21 and 16 per cent. There was no significant difference
between the treatment arms in terms of pCR or downstag-
ing, but an increased rate of acute toxicity was reported
in the irinotecan group. Gollins and colleagues48 reported
on 110 patients with MRI-defined locally advanced rectal
© 2018 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2018; 105: 1553–1572
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Table 2 Summary of other chemotherapy agents
Results (%)*
Reference Phase Disease stage Test drug
Single/
combination Cohort size pCR rate cCR rate Other endpoints Toxicity
38 III T3–4N–/+ Oxaliplatin Capecitabine +
oxaliplatin
versus
capecitabine
alone
598 19⋅2 (13⋅9) 0⋅7 (0) Positive CRM 9⋅9
(19⋅3)
Grade 3–4 toxicity
25 (1)
39 III T3–4N–/+ Oxaliplatin 5-FU+oxaliplatin
versus 5-FU
alone
1236 17 (13) – 3-year DFS 75⋅9
(71⋅2)
Grade 3–4 toxicity
23 (20)
40 III T3–4N–/+ Oxaliplatin 5-FU +/–
oxaliplatin
versus
capecitabine
+/– oxaliplatin
1608 – – LR 11⋅2 (11⋅8)
5-year DFS 66⋅4
(67⋅7)
5-year OS 81⋅3
(79)
Addition of
oxaliplatin
significantly
increased
toxicity
(P<0⋅001)
41 III T3–4N–/+ Oxaliplatin Oxaliplatin +5-FU
versus 5-FU
alone
1094 – – 3-year DFS 74⋅5
(73⋅9)
–
42 III T3–4N–/+ Oxaliplatin 5-FU+oxaliplatin
versus 5-FU
alone
747 16 (16) – Positive CRM 7 (4) Grade 3–4 toxicity
24 (8)
Discontinued
owing to toxicity
17 (4)
43 III T3–4N–/+ Oxaliplatin 5-FU+oxaliplatin
versus 5-FU
alone
495 27⋅5 (14⋅0) – Negative nodes
87⋅4 (80⋅1)
Grade 3–4
haematological
toxicity 19 (12⋅9)
44 I–II T3–4N–/+ Irinotecan Irinotecan +5-FU 59 25 – Downstaging 41
3-year DFS 40
Grade 3–4 toxicity
28⋅8
45 II T3–4N–/+ Irinotecan Irinotecan +
capecitabine
36 15 – 3-year OS 80 Grade 3–4
haematological
toxicity 25
46 II T3–4N–/+ Irinotecan Irinotecan +
capecitabine
48 25 – 5-year DFS 75
5-year OS 94
Grade 3 toxicity
10⋅5
No grade 4 toxicity
47 II T3–4N–/+ Irinotecan Irinotecan + 5-FU
versus 5-FU
alone
106 26 (30) Downstaging 75
(74)
5-year OS 75 (61)
5-year DFS 85 (78)
Grade 3 toxicity
13 (8)
48 II T3–4N–/+ Irinotecan Irinotecan +
capecitabine
110 21⋅8 – Negative CRM
89⋅1
3-year DFS 96⋅9
3-year OS 88⋅2
Grade 3 GI
toxicity 22
No grade 4 toxicity
*Results for control group are shown in parentheses. pCR, pathological complete response; cCR, clinical complete response; CRM, circumferential
resection margin; 5-FU, 5-fluorouracil; DFS, disease-free survival; LR, local recurrence; OS, overall survival; GI, gastrointestinal.
cancer threatening or involving the surgical CRM treated
with a regimen of irinotecan 60mg/m2 weekly for the first
4weeks of a 5-week course of capecitabineCRT. In total, 24
patients (21⋅8 per cent) had a pCR and 98 (89⋅1 per cent)
a negative CRM. A further study focusing on long-term
outcome in 115 patients57 found no significant difference
between the two treatment arms in terms of pCR, with a
higher overall survival rate of 87 per cent and DFS rate
of 79 per cent in the irinotecan group (median follow-up
60months).
Despite the promise of the above studies, no phase III
trial of concurrent irinotecan has yet been reported58.
This will be rectified in the future by the ongoing UK
ARISTOTLE trial, which will complete accrual (target
600 patients) in mid-2018. InMRI-defined high-risk rectal
cancer, ARISTOTLE will compare CRT with concurrent
capecitabine with or without irinotecan.
Epidermal growth factor receptor inhibitors
Epidermal growth factor receptor (EGFR), a member of
the ErbB family of receptors, is relevant in colorectal can-
cer because overexpression or upregulation of the EGFR
gene occurs in 60–80 per cent of cases59–61. Expression
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Table 3 Summary of phase II trials of epidermal growth factor receptor inhibitors
Results (%)*
Reference Phase
Disease
stage Test drug
Single/
combination Cohort size pCR rate cCR rate Other endpoints Toxicity
66 II T3–4N–/+ Panitumumab Single 19 0 – Downstaging 41
Negative CRM 76
LRC 90
DFS 79
GI disturbance 89
Grade 4 toxicity 21
67 II T3–4N–/+ Cetuximab Cetuximab +
capecitabine
31 0 – Downstaging 42 GI disturbance 13
Grade 4 toxicity 3
68 II T3–4N–/+ Panitumumab Panitumumab +
oxaliplatin +5-FU
60 21 – Downstaging 58 GI disturbance 39
1 death
69 II T3–4N–/+ Panitumumab Panitumumab +
capecitabine
versus
capecitabine alone
68 10 (18) – R0 resection
85 (93)
Sphincter salvage
69 (70)
Downstaging
87 (85)
GI disturbance
10 (4)
70 II T3–4 Cetuximab Cetuximab +
capecitabine +
oxaliplatin versus
capecitabine +
oxaliplatin
165 11 (9) 11 (7) Radiological
response 71 (51)
GI disturbance
8 (9)
71 II T2–4N–/+ Cetuximab Cetuximab +
capecitabine +
irinotecin
82 17 5 R0 resection 82 GI disturbance 25
Grade 4 toxicity 10
72 II T3–4N–/+ Cetuximab Cetuximab +
capecitabine
47 8 – 3-year DFS 72
3-year RFS 74
3-year OS 68
2 of 32 unable to
complete
treatment owing
to GI
disturbance and
leucopenia
73 I–II T3–4N–/+ Cetuximab Cetuximab +
capecitabine +
oxaliplatin
60 8 – 5-year OS 76
3-year DFS 88
5 -year CSS 78
Grade 2 toxicity 5
*Results for control group are shown in parentheses. pCR, pathological complete response; cCR, clinical complete response; CRM, circumferential
resection margin; LRC, locoregional control; DFS, disease-free survival; GI, gastrointestinal; 5-FU, 5-fluorouracil; RFS, relapse-free survival; OS, overall
survival; CSS, cancer-specific survival.
of the gene is also associated with poor survival62–64. The
anti-EGFR monoclonal antibodies cetuximab and panitu-
mumab are already approved for the treatment of RAS
wild-type metastatic colorectal cancer65, but their role in
LARC remains unclear.
There have been several clinical trials of EGFR-targeting
monoclonal antibodies as radiosensitizers in neoadjuvant
therapy for LARC. These trials are summarized in Table 3.
Early efficacy results in terms of pCR rate were around
5–10 per cent74–76. However, these studies did not
investigate tumour RAS status, which is used as a pre-
dictive biomarker for anti-EGFR monoclonal antibody
response in metastatic colorectal cancer77,78. Potentially,
optimal ordering of chemotherapy, RT and the EGFR
inhibitor might unlock the full radiosensitizing potential
of anti-EGFR monoclonal antibodies79.
A phase II trial66 was designed to assess the pCR
(primary endpoint) following neoadjuvant therapy with
panitumumab and RT. Of 19 enrolled patients, 17 were
evaluable for pathology assessment. Although no pCR
was observed, seven patients (41 per cent) had grade 3
Dworak pathological tumour regression. As the primary
endpoint was not achieved, the authors were unable to
make any recommendation for the use of panitumumab
in treatment of LARC. Similar findings were reported in
other phase II trials where the primary endpoint of pCR
was not achieved67,68, and toxicity was high69.
EXPERT-C70 was a randomized phase II trial of neo-
adjuvant CAPOX with or without cetuximab, followed
by capecitabine-based CRT with or without cetuximab,
followed by surgery and then adjuvant CAPOX with or
without cetuximab in 165 high-risk patients with rectal
cancer. Cetuximab did not improve the primary outcome
(pCR), so it was not felt to have contributed significantly to
increased radiation-induced cytotoxicity. The EXPERT-C
trial did, however, find that TP53 tumour suppressor
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protein wild-type status was a predictive biomarker in
favour of cetuximab-based therapy.
The prospective phase II EXCITE trial71, published
in 2017, focused on the addition of cetuximab to an
irinotecan–capecitabine-based neoadjuvant CRT regimen
in 82 patients. Fourteen patients (17 per cent) had a
pCR. As a side point of interest, contrary to the planned
protocol, four patients achieved an endoscopically and
MRI-confirmed cCR, and were managed using the emerg-
ing watch-and-wait approach. Overall 24 patients (29 per
cent) had an excellent clinical or pathological response.
Using next-generation sequencing, 46 per cent of matched
biopsy–resection specimens were discrepant for EGFR
pathway mutations. Intratumoral heterogeneity was sug-
gested as a possible explanation, manifesting as a geograph-
ical biopsy miss or chemoradiation-driven emergence of
new mutations.
Phase II studies so far have failed to suggest a benefit in
terms of pCR rate and DFS, and have shown no consistent
correlation with KRAS status72,73,80. There is currently
no role for the addition of EGFR-targeted therapy as a
radiosensitizer in the treatment of LARC81. However, a
pilot study82 of RT with personalized chemotherapy and
biological therapy, based on molecular markers among 16
patients with T3 or N1 rectal cancers, showed a pCR rate
of 50 per cent, which may be the basis for future molecular
guided studies.
Antiangiogenesis therapy
Bevacizumab
Bevacizumab is a monoclonal antibody that targets vascu-
lar epithelial growth factor (VEGF). In combination with
cytotoxic chemotherapy, it has shown potential for rectal
cancer treatment; the evidence is, however, currently lim-
ited to phase I–II trials83. Salazar et al.84 undertook amulti-
centre randomized phase II trial in 90 patients with LARC,
of capecitabine with or without bevacizumab. The pCR
rate was 16 per cent in the bevacizumab arm, compared
with 11 per cent in the control arm, and an additional
20 per cent of tumours were downstaged. However, the
predefined efficacy endpoint of a difference in treatment
arms of 10 per cent was not met, despite these encouraging
results.
Landry et al.85 performed a phase II trial of the addi-
tion of bevacizumab therapy with 5-year follow-up. Of 57
patients included in the data analysis, 17 per cent achieved a
pCR, with an overall 5-year survival rate of 80 per cent and
relapse-free survival rate of 81 per cent. The pCR endpoint
of 30 per cent was not reached and, owing to substantial
side-effects (1 death was attributed to study therapy), the
regimen was not considered worthy of further work by the
authors.
Sorafenib
Sorafenib is a multikinase inhibitor that blocks the
receptor tyrosine kinase of VEGF, platelet-derived
growth factor and the RAF serine–threonine kinases
along the RAF–mitogen-activated protein kinase
kinase–extracellular signal-related kinase pathway. Jeong
and colleagues86 assessed its potential as a radiosensitizer
using three colorectal cell lines, and a xenograft animal
model. They were able to demonstrate a scientific rationale
for combination therapy, with enhanced radiosensitivity
being shown in all three cell lines and the xenograft model,
and delayed DNA damage repair caused by the radiation
treatment. Van Moos et al.87 evaluated its effect in a cohort
of 54 patients with KRAS-mutated rectal tumours in
combination with capecitabine-based CRT. The pCR rate
was 60 per cent, with downstaging in 82 per cent. A second
phase I study88 also produced encouraging results, with a
pCR of 36 per cent.
Poly(ADP-ribose) polymerase inhibition
PARPs, particularly PARP-1, play a critical role in the
recognition and repair of DNA single- and double-strand
breaks. Higher PARP activity has been noted in
cancer cells with increased proliferation and chemoradio-
resistance, and this has led to the development of PARP
inhibitors, which reduce the cancer cell’s ability to repair
single- and double-strand breaks generated by RT and
lead to cell death. Preclinical trials have demonstrated
radiosensitizing effects in multiple colorectal cell lines89,
although this effect is potentially largely dependent on
the status of oncogenes such as BRCA1/BRCA290 gener-
ating defective DNA double-strand break repair (termed
synthetic lethality), and dysregulation of P5391.
Veliparib (ABT-888), a potent orally bioavailable
PARP-1/2 inhibitor, has been shown to enhance the
antitumor activity of chemotherapy and RT in preclin-
ical colorectal cancer models92. In in vitro and in vivo
experiments in colorectal cancer, veliparib had indepen-
dent radiosensitization effects and was synergistic with
chemotherapy, especially with irinotecan. Final results
from a phase Ib dose-escalation study of veliparib plus
capecitabine-based CRT and surgery were published in
201793, demonstrating a pCR rate of 28 per cent. As with
the EGFR monoclonal antibodies, this class of potential
radiosensitizer remains an area of interest and future
studies are needed to elucidate its role in rectal cancer.
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Potential predictive biomarkers have not been identified.
A recent report94 has described pharmacodynamic assays
that are able to measure the low levels at which PARP
inhibitors are active.
Immunotherapy
The immune system plays an intricate and complex role
in all aspects of cancer from carcinogenesis to treatment95.
Over the past 10 years, a great deal of work has been
done to better understand that role, with the develop-
ment of therapies such as programmed cell death protein
1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors,
cancer vaccines and adoptive cell therapy. In a phase
I–II trial96 of adjuvant immunotherapy involving sentinel
lymph node T lymphocytes in 55 patients with metastatic
colorectal cancer, there was no treatment-related toxicity,
and 24-month survival rates were 56 and 18 per cent in the
treatment and control groups respectively.
Use of cytokine therapy, although very early in terms
of research into colorectal cancer, has been approved by
the US Food and Drug Administration for melanoma and
renal cell carcinoma (interleukin 2). Although much of
the work focusing on colorectal malignancy is in its early
phases (I–II), there is evidence to suggest the potential
use of these therapies in a combination role for a correctly
selected cohort97. Specifically, the PD-1 immune check-
point inhibitors pemrolizumab and nivolumab have shown
promising activity in DNA mismatch repair-deficient
(dMMR)/microsatellite instability – high colorectal can-
cers, which carry a high mutation load and an active
immune microenvironment98,99. A small proportion of
rectal cancers are dMMR, but one possible area of research
is to determine whether the proinflammatory properties
of RT might enhance the response of microsatellite-stable
tumours to PD-1 blockade. The R-IMMUNE phase II
study100 is currently recruiting to compare the use of
atezolizumab as a radiosensitizer with 5-FU-based neo-
adjuvant CRT. More studies are in the pipeline, with a
recent UK proposal aiming to assess the effect of the
PD-L1 inhibitor durvalumab in combination with RT.
Novel agents
With a clear focus of research on optimizing neoadjuvant
therapy, several novel agents ranging from cyclo-oxygenase
2 inhibitors to nanoparticles have been investigated in the
preclinical setting (Table 4). Further phase I studies are
in preparation to examine both prostaglandin E2 recep-
tor inhibitors (PRAER 1 trial) and Ad3/Ad11p chimeric
adenoviruses (CEDAR trial).
Alternatives to standard radiotherapy
strategies
Dose escalation
An alternative potential method of enhancing the effec-
tiveness of CRT is by increasing the radiation dose,
via an increased external-beam dose or endocavitary
brachytherapy. There is evidence to suggest that a
dose–response relationship with pCR exists114.
A prospective single-centre study115 from Denmark in
patients with T2–3 cancers within 6 cm of the anal verge
used radiation dose intensification to the primary tumour
delivered with intensity-modulated external-beam RT to
60Gy in 30 fractions over 6weeks, with 50Gy to the pelvic
nodes, combined with an endorectal brachytherapy tumour
boost to 5Gy and tegafur/uracil on treatment days. Of the
51 patients treated, 78 per cent achieved a cCR and organ
preservation; the local recurrence rate was 26 per cent at
2 years. Grade 3 diarrhoea occurred in 8 per cent, and
long-term rectal bleeding was of concern during follow-up.
Gerard and colleagues116 demonstrated improved clinical
(24 versus 2 per cent) and pathological (57 versus 34 per
cent) responses using the 50-Kv Papillon technique for
contact X-ray brachytherapy (CXB). Patients with a clinical
incomplete response to external-beam CRT have been
shown to achieve a cCR after a CXB boost, with only 11
per cent developing recurrence117.
With both approaches, there is a lack of randomized
data. The recently funded UK APHRODITE study will
randomize patients with T1–T3b rectal adenocarcinomas
with a maximum diameter of 4 cm, considered unsuitable
for radical TME surgery, to standard CRT versus RT
dose-escalated CRT. The OPERA trial will randomize
patients with early cT2–T3a–b tumours smaller than 5 cm
in diameter, treated with external-beam CRT, to either an
external-beam CRT boost or a CXB boost.
Delivery modification
An alternative strategy to dose escalation is the develop-
ment of novel delivery methods that reduce toxicity, par-
ticularly to the small bowel. Intensity-modulated RT is
one such technique that has been proposed owing to its
highly conformal dose distribution. There are currently
few published prospective data to support its routine use;
however, a recent meta-analysis118 of retrospective stud-
ies has suggested that it has a significantly lower toxicity
profile than routine three-dimensional CRT. Future devel-
opments may ultimately lead to traditional photon irradia-
tion being replaced with charged particles such as protons
or carbon ions, which may have even greater biological
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Table 4 Summary of novel radiosensitizing agents
Reference Study design Findings
COX-2 inhibitors Cox-2 is an inducible enzyme that regulates prostaglandin synthesis and is overexpressed at sites of inflammation and in
epithelial malignancy tumours101. It is involved in the regulation of apoptosis, angiogenesis and tumour cell invasiveness.
Preclinical studies suggest the potential of COX-2 inhibitors as selective radiosensitizers102
Debucquoy et al.103 Double-blind randomized phase II; in addition to 5-FU; 35
patients
Improved downstaging
No increased toxicity
Nanoparticles Aim to improve the therapeutic index of chemoradiotherapy and overcome potential systemic excess toxicity. Focus on
particle size sub-50 nm
Caster et al.104 Particles 50, 100 and 150nm in size loaded with 2 DNA
repair inhibitor model drugs in colorectal cancer cell lines
All sizes potent radiosensitizers
Good toxicity tolerance
Tian et al.105 CRLX101 in combination with oxaliplatin and 5-FU Increased efficacy of chemoradiotherapy
Early stage; needs expansion
Histone deacetylase
inhibitors
Emerging therapeutic concept attempting to target epigenetic regulatory mechanisms and act as a radiosensitizer in
combination therapy. SAHA approved as a single agent for refractory cutaneous T-cell lymphoma
Folkvord et al.106 Preclinical study of SAHA using 2 xenograft models In vitro: improved radiosensitivity (P≤ 0⋅050) across cell
lines at all radiation doses less than 6 h after exposure
In vivo: pCR achieved in 1 model
Saelen et al.107 Vorinostat assessed under hypoxic conditions in vitro Enhanced radiosensitivity across cell lines
Warrants further research
Small molecular inhibitors Low molecular weight; able to target both extracellular and intracellular proteins
Kleiman et al108 Preclinical
Focus on radiosensitizers for KRAS mutant tumours
28 known radiosensitizers assessed
6 effective; AZD7762 most highly potent
Suggested investigation into role of CHK2 inhibitors
Nelfinavir HIV protease inhibitor; inhibits Akt at standard clinical doses and results in radiosensitivity
Hill et al.109 Non-randomized SONATINA clinical trial focusing on safety
in 10 patients with T3–4N0–2M1 rectal cancers
recruited over 2 years
14days total oral treatment (7 days preoperative)
2 discontinued owing to toxicity
5 grade 3 toxicity
Warrants further research
Buijsen et al.110 Phase I trial including 12 patients
Escalating doses with capecitabine
Primary endpoint: dose-limiting toxicity
4 of 6 experienced toxicity, precluding further dose
escalation
pCR 27%
Further toxicity concerns
Zerumbone Cyclic sesquiterpene from rhizomes of edible ginger plant; emerging evidence of potential for inhibition of proliferation of
human colonic adenocarcinoma cells, with minimal toxicity111
Deorukhkar et al.112 3 colorectal cancer cell lines
Inhibition of proliferation identified in dose-dependent
manner
Marked radiosensitizer in clonogenic survival curves
Little effect on normal fibroblasts
Warrants further research
Bortezomib Modified dipeptidyl boronic acid derived from leucine and phenylalanine that acts as a 26S proteasome inhibitor. The
ubiquitin–proteasome pathway is involved in intracellular protein degradation in eukaryotic cells
O’Neil et al.113 10 patients with stage II or III rectal cancer received
5-FU-based chemoradiotherapy plus bortezomib twice
per week
pCR 10%
High toxicity – diarrhoea
Study not progressed
COX, cyclo-oxygenase; 5-FU, 5-fluorouracil; SAHA, suberoylanilide hydroxamic acid; pCR, pathological complete response; CHK2, serine–threonine
kinase 2; HIV, human immunodeficiency virus.
effectiveness while maintaining a favourable toxicity pro-
file. At the present time, further clinical studies and access
to treatment facilities are required to assess the applicability
of these techniques fully119,120.
Preoperative chemotherapy given sequentially
with (chemo)radiotherapy
The twofold rationale for giving neoadjuvant chemother-
apy sequentially, either before or after (C)RT, followed
by surgery, is to improve the response of the primary
tumour and to reduce the distant metastasis rate. Owing to
morbidity from RT and pelvic surgery, individuals who
have undergone preoperative CRT then surgery may fail
to start adjuvant chemotherapy or tolerate it poorly, result-
ing in dose reductions121. A meta-analysis122 of four trials
including preoperative RT, however, has questioned the
benefit of postoperative chemotherapy (hazard ratio for
DFS 0⋅91, 95 per cent c.i. 0⋅77 to 1⋅07; P= 0⋅230), pos-
sibly for this reason. Giving chemotherapy before surgery
allows an increased dose intensity to be delivered, poten-
tially increasing the response rate.
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However, although the concept of ‘total neoadjuvant
therapy’ is gaining traction123, there is currently very little
randomized phase II (and no phase III) evidence specifi-
cally examining the benefit of neoadjuvant chemotherapy.
Grupo Cancer de Recto (GCR) 3124 was a randomized
phase II study of preoperative CAPOX followed by CRT
then surgery versus CRT then surgery then postoperative
CAPOX in 108 patients. Less toxicity (P< 0⋅001) and
better compliance (P< 0⋅001) were demonstrated for the
same regimen used as neoadjuvant chemotherapy compared
with adjuvant chemotherapy, although the pCR rate was no
different (13 versus 14 per cent respectively).
A non-randomized US–Canadian trial125 examined four
sequential study groups of patients with LARC, examining
CRT followed by chemotherapy then surgery. Group 1 had
CRT followed by TME 6–8weeks later. Groups 2, 3 and 4
had two, four and six 2-weekly cycles ofmodified FOLFOX
delivered between CRT and TME. The pCR rate was
18, 25, 30 and 38 per cent for groups 1–4 respectively.
Although promising, it is not clear whether the increased
downstaging occurred because of a greater gap between
CRT and surgery (6, 8, 12 and 16weeks for groups 1–4
respectively).
Randomized studies are urgently needed to examine the
efficacy of intensified neoadjuvant CRT regimens for rec-
tal cancer, including the sequential addition of preopera-
tive chemotherapy, in comparison to standard neoadjuvant
CRT alone.
Neoadjuvant chemotherapy alone
In the modern TME era, local recurrence rates have fallen
to as low as 5 per cent. However, CRT has not affected
distant metastatic relapse, which affects up to 30 per cent
of patients. Although surgery is associated with long-term
sexual, bowel and bladder dysfunction, preoperative RT
can exacerbate this morbidity126. Consideration should be
given to whether chemotherapy alone can be as effective
as CRT in terms of DFS, thereby avoiding some acute and
long-term toxicity.
Several small single-arm studies using mainly
oxaliplatin-based chemotherapy have reported promising
DFS rates. In addition, studies127,128 examining neoadju-
vant CAPOX followed by CRT have clearly shown the
substantial downstaging efficacy of chemotherapy, using
MRI after chemotherapy but before CRT. The FOWARC
Chinese phase III study43 randomized 495 patients with
LARC to either standard neoadjuvant CRT using concur-
rent 5-FU, CRT with concurrent 5-FU and oxaliplatin, or
FOLFOX chemotherapy alone. Although tumour down-
staging was comparable between the standard CRT and
chemotherapy-alone arms (37⋅1 and 35⋅5 per cent respec-
tively), the pCR rate was inferior with chemotherapy alone
(14⋅0 versus 6⋅6 per cent). It was reported recently that
there was no difference in DFS or overall survival between
the three arms129. At present, there is more evidence
to support the replacement of neoadjuvant CRT with
chemotherapy using DFS as the primary endpoint, than
for a cCR/organ preservation endpoint.
Discussion
The ideal radiosensitizing agent would be one that could
target cancer cells selectively130,131, enhancing the effi-
cacy of treatment with minimal local and systemic toxicity.
Exploiting the benefits of neoadjuvant therapy, accurately
staging and assessing cCR could open up the era of increas-
ingly personalized medicine and the avoidance of resec-
tion altogether132. It is an area of research that could
bring significant patient benefits including improvements
in health-related quality of life.However, future clinical tri-
als of radiosensitizers, with the aim of organ preservation,
need carefully to consider the endpoints that are used to
assess efficacy132.
Although there is much emerging evidence with regard
to potential new radiosensitizing agents, the current stan-
dard treatment alongside RT remains 5-FUor capecitabine
chemotherapy. The addition of any second systemic agent
has yet to show a consistent increase in efficacy in random-
ized studies. Many promising radiosensitizers have failed
to progress beyond the preclinical and early clinical phases
(I–II) owing to systemic toxicity and varying rates of pCR.
Unfortunately, the quality of phase II studies of potential
intensifying agents has been poor. A systematic review133 of
92 phase II trials showed that only eight were randomized.
There remains the fundamental question of the optimal
primary endpoint. In virtually all studies in this review,
the pCR rate was employed as the determinant of suc-
cess. At present, there is no predetermined set definition
of what constitutes a pCR. It may be defined as the absence
of neoplastic cells in the surgical resection specimen as a
result of neoadjuvant treatment (ypT0 and ypN0)134 and
indeed may still occur even in the presence of mucosal
abnormalities following treatment135. Published rates of
pCR range widely from 15 to 40 per cent136,137. How-
ever, despite small cohort sizes being accounted for, very
few trials have noted the potential introduction of bias due
to lack of standardization of pathologist reporting. The
Royal College of Pathologists138 specifies that patholo-
gists should embed all of the tumour-associated scar and
examine three deeper levels on each block before calling a
pCR. The lack of reliable lymph node involvement status,
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dependence on pathologist block and level sampling inten-
sity, and varying time points between the end of RT and
surgery affecting tumour regression, could potentially lead
to inflated pCR results. The associated benefits of a true
pCR include a reduced recurrence rate and enhanced over-
all survival136,139,140.
Tumour regression grading is a semiquantitative assess-
ment of residual tumour cells versus fibroinflammatory tis-
sue in the rectal wall, and has been shown to be able to
stratify tumour response to CRT and predict prognosis on
an individual-patient level in two large prospective phase
III trials141,142. Identifying patients who have achieved a
cCR following CRT, and who could be followed prospec-
tively with an active surveillance or watch-and-wait strat-
egy, is gathering increasing interest. Of 183 patients with
T2–T4N0–2M0 distal rectal cancers receiving neoadju-
vant CRT in a trial published in 2014 by Habr-Gama and
colleagues143, 49 per cent were deemed to have achieved
a cCR; 31 per cent of these patients went on to develop
local recurrence and the salvage rate was 93 per cent.
The rate of local disease control was 94 per cent, with
78 per cent organ preservation. The Habr-Gama proto-
col involved clinical, endoscopic, radiological and serolog-
ical reassessment of patients 8weeks after completion of
neoadjuvant therapy. A cCR was defined as the absence of
residual ulceration, stenosis or mass lesion within the rec-
tum on digital palpation and endoscopic imaging. MRI was
performed, and the carcinoembryonic antigen level was
measured.
The International Watch & Wait Database
Consortium144 recently published the long-term out-
comes of the largest series of patients managed by this
strategy, reporting a 2-year cumulative regrowth rate of
25⋅2 per cent among 1009 patients. Surgical treatment
data were available for only 148 of the 213 patients who
experienced regrowth; 115 proceeded to TME resection,
with histologically clear margins in 88 per cent. Overall
5-year survival rates of 84⋅7 per cent in this group are com-
parable to those of major resection. However, before this
approach can be established as a standard of care, standard-
ized definitions of cCR and surveillance protocols need
to be developed. Criteria for shared decision-making with
the patient for this approach also need to be addressed.
An increasing consensus views a two-stage assessment as
optimum for identifying a cCR, at 3 and then 6months
following CRT, allowing enough time for a cCR to develop
in initially good responders145. MRI tumour regression
grade following CRT has been shown to be predictive of
DFS in a cohort of 66 patients from theMERCURY study,
suggesting the value of MRI assessment after CRT as part
of the protocol for selecting patients for a non-operative
approach146. Although there are still many questions sur-
rounding watch and wait147, it clearly has an increasingly
important place in modern rectal cancer management and
strategies to intensify CRT need further exploration.
For patients in whom there has been a good response
but not an apparent cCR, local transanal excision is an
alternative to major resection148,149. MRI can be useful
in guiding patient selection for such treatments150. How-
ever, the recently published GRECCAR 2 study151, which
used a composite endpoint of surgical complications and
recurrence, failed to show a difference between the two
approaches in this setting, suggesting that more prospec-
tive studies are needed in this area.
It is imperative that studies employ standardized patho-
logical reporting to ensure that the pCR rates quoted are
both realistic and comparable. In view of this, use of the
pCR as a primary endpoint for research studies and/or clin-
ical trials should perhaps be questioned. If the ultimate
goal is organ preservation regardless of whether the patient
has undergone a cCR or pCR, perhaps organ preservation
should be the primary endpoint. Against this is the mor-
bidity associated with rectal surgery in terms of bowel, uri-
nary and sexual dysfunction. However, there are few data
on long-term toxicity and health-related quality of life for
an active surveillance approach, which clearly needs to be
addressed in future prospective studies. A recent patient
consultation exercise revealed that, even in the context
of cancer care, patients regarded quality of life and pres-
ence of a stoma as more important than overall survival152.
Future trials of neoadjuvant therapy for rectal cancer need
to ensure that patient experience and reported endpoints
are addressed.
Although not available at the present time, it is hoped
that the development of biomarker-based stratified treat-
ment will be used to guide neoadjuvant therapy on a per-
sonalized basis in the future153. Such biomarkers may be
purely molecular (DNA alterations, gene expression, pro-
tein expression, epigenetic or circulating) or a combina-
tion ofmolecularmarkers and imaging findings154. Reliable
pretreatment biomarkers do not currently exist, although
ongoing research is attempting to identify pretreatment
markers that are predictive of response155,156. It is essential
that future neoadjuvant trials incorporate a translational
element to further develop biomarker-guided therapy. As
such, it is critical that such translational arms adhere to
a robust biopsy protocol to ensure that enough appropri-
ate biological material is available for downstream analysis
in addition to the routine histopathological biopsies taken
for diagnostic purposes. Factors that need to be consid-
ered include the person taking the biopsies, the quantity
of material and timing. Patients who undergo a cCR or
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pCR will have little or no tumour to access at either clinical
follow-up or at the time of surgical resection; this must be
considered in the translational design, which may need to
include liquid biopsies157.
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